Table 3 Determinants of cIMT, cCD, and plaques modifications after 1 year of follow-up in the whole sample of RA patients in multivariable analysis

From: Traditional cardiovascular risk factors and residual disease activity are associated with atherosclerosis progression in rheumatoid arthritis patients

RA (n = 105)

ΔcIMT (beta coeff/SEM; p value)

ΔcCD (beta coeff/SEM; p value)

ΔPlaques (beta coeff., [95% I.C]; p value)

Male sex

N.s.

N.s.

3.752 [1.323–10.640]; p = 0.01

Age

N.s.

N.s.

1.140 [1.082–1.202]; p < 0.001

BMI

N.s.

N.s.

N.s.

MAP

N.s.

−0.12 ± 0.04; p = 0.002

1.038 [1.003–1.073]; p = 0.003

HR

N.s.

N.s.

N.s.

Diabetes

0.102 ± 0.037; p < 0.005

−6.00 ± 2.18; p = 0.007

N.s.

Dyslipidemia

N.s

N.s

N.s

Smoke status

N.s

N.s

N.s

RA duration

N.s

N.s

N.s

RF

N.s

N.s

N.s

Anti-CCP

N.s

N.s

N.s

AHT

N.s.

N.s.

N.s.

Corticosteroids

N.s.

−2.67 ± 1.54; p = 0.021

N.s.

DMARDs

N.s.

N.s.

N.s.

Biological drug

N.s.

N.s.

N.s.

DAS28 [CRP]

N.s.

N.s.

N.s.

  1. cIMT carotid intima media thickness, cCD common carotid distensibility, BMI body mass index, MAP mean arterial pressure, HR heart rate, RA rheumatoid arthritis, RF rheumatoid factor, anti-CCP anti-citrullinated cyclic peptide, AHT anti-hypertensive therapy, Corticosteroid dose > than 10 mg of prednisolone or equivalent; DMARDs disease modifying drugs, DAS28[CRP] disease activity score 28 [C Reactive Protein], N.s. not significant
Back to article page